A company may disclose that insiders intend to purchase shares of the offering. Investors normally appreciate that they are purchasing at the same price as insiders (though their cost basis will still be much lower). This also reduces the float, as insiders are restricted from selling. Insider buying is very common for biotech IPOs, and not uncommon for technology deals. Disclosing insider buying when a company files its terms is generally viewed as a positive. However, adding insider buying after the IPO has launched often indicates weak demand for the deal.